2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.16 Curt

PP01.16 Curt - Abstract

Pdf Summary

A study conducted on Veterans receiving lurbinectedin for small cell lung cancer (SCLC) found that their outcomes were less favorable compared to clinical trial patients. The study, which included 415 patients with a median age of 70 and predominantly male, revealed a median survival of 4.8 months, with 12- and 24-month survival rates at 17.6% and 8.9% respectively. Factors associated with worse survival included a chemotherapy-free interval of 90 days, lower body mass index, higher frailty, and baseline chronic obstructive pulmonary disease. The study highlighted the challenges of treating high-risk SCLC patients, particularly in Veterans with a history of significant tobacco use. The findings suggest that the real-world benefits of lurbinectedin may be limited in this population, underscoring the need for more effective and innovative SCLC therapies.

Keywords

Veterans

lurbinectedin

small cell lung cancer

SCLC

clinical trial

survival rates

chemotherapy-free interval

frailty

chronic obstructive pulmonary disease

tobacco use